Oncology

Celltrion Refutes Critique of CT-P13 Equivalence

August 14th 2020

By Deana Ferreri, PhD

Article

Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.

Automatic Substitution Pays Off for Compass Oncology West

August 14th 2020

By Skylar Jeremias

Article

Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.

Pfizer Expert Urges Employers to Get Proactive on Biosimilars

August 13th 2020

By Tony Hagen

Article

Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.

Disney Official, Others Talk About Switch to Biosimilars

August 13th 2020

By Tony Hagen

Article

Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.

At University of Missouri Health Care, Biosimilars Are Transformative but Somewhat Restricted

August 12th 2020

By Tony Hagen

Article

Pharmacy experts discuss their level of confidence with biosimilars and some of the hurdles that stand in the way of optimizing these lower-cost medicines.

Polpharma Biologics: The Polish Biosimilar Powerhouse

August 11th 2020

By Skylar Jeremias

Article

Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.

Sandoz Rituximab Measures Up in DLBCL

August 10th 2020

By Tony Hagen

Article

A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.

Samsung Bioepis Enters Breast and Gastric Market in Brazil

August 10th 2020

By Tony Hagen

Article

Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.

Study: How Out-of-Pocket Caps Affect Payer Policy

August 7th 2020

By Tony Hagen

Article

Investigators set out to learn whether the imposition of out-of-pocket spending caps on specialty drugs would unleash a wave of drug spending and prompt payer policy change.

Lyman Reassures on Biosimilar Quality

August 6th 2020

By Tony Hagen

Article

Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.